Costs of peripheral blood progenitor cell transplantation using whole blood mobilised by filgrastim as compared with autologous bone marrow transplantation in non-Hodgkin's lymphoma.
The aim of this paper is to compare the costs of autologous bone marrow transplantation (ABMT) and whole blood transplantation in patients with relapsed or poorly responding non-Hodgkin's lymphoma. In a retrospective study, we calculated the treatment costs of 40 patients who received either ABMT or, alternatively, whole blood mobilised by filgrastim (a granulocyte colony-stimulating factor. The recovery of granulocytes was markedly accelerated in the whole blood group as compared with the ABMT group. This resulted in a reduction in hospital costs, and costs for diagnostics and medical procedures, antibacterials, nutrition and blood transfusions. The average costs per patient in the whole blood group amounted to approximately $US16,890 as compared with approximately $US20,713 in the ABMT group (1995 values), implying a cost reduction of 18% when changing to whole blood reinfusion. With the premise that both therapies are equivalent, it seems that whole blood transplantation is more cost effective than ABMT.